



ASX & MEDIA RELEASE

30 OCTOBER 2018

MEDLAB SUCCESSFULLY COMPLETES STAGE 1 OF NANABIS™ CANCER TRIAL. SAFETY DATA GOOD, PROCEEDING TO STAGE 2

- Successful completion of Stage 1 of human cancer trial at Royal North Shore Hospital (RNS)
- Independent Data Safety Monitoring Board (DSMB) approve proceeding to Stage 2 of the trial focusing again on safety but also, dosage escalation and tolerance
- Exciting early results reported on pain reduction

Australian medical life sciences company, Medlab Clinical Ltd (ASX: MDC) is pleased to announce that it has successfully completed stage 1 of the NanaBis™ (Medlab's cannabis-based medicine) human trial on cancer patients at RNS and has received formal approval from the DSMB to proceed to Stage 2 of the human cancer trial.

At this point, Medlab would like to thank the DSMB members for their time and support.

Stage 2 of the Clinical Trial will focus on further safety but also tolerance and dose escalation. In Stage 2, we continue with cancer patients but this time with unmanaged pain.

With regards to some key data findings from the Stage 1 group, Medlab is extremely pleased to report:

- NanaBis™ is safe
- NanaBis™ is effective up to nine hours following a single dose administered
- NanaBis™ levels detected at first blood draw at 30 minutes
- NanaBis™ is at maximum concentration (also known as Tmax*) in the plasma, based on 1 dose, in as little as 1.25 hours
- Early indications confirm that NanaBis™ helps with pain reduction

According to Prof Luis Vitetta, Director of Medical Research, at Medlab "this is an extremely encouraging result, from all aspects of the data that we are seeing."

Dr Sean Hall, CEO of Medlab stated, "these results confirm and validate our original hypothesis and offer a true alternative to current pain medications. I'm looking forward to data from Stage 2. Although pain measurement was not a key part of Stage 1, the early results of pain reduction while being administered NanaBis™ was very encouraging."

**Tmax is a global pharmacology term used to define peak concentrations of an active ingredient in plasma (blood) at a timepoint*

Trial Background Information

The RNS trial has 2 distinct stages. Stage 1 is a safety and tolerability phase where patients are admitted into hospital for 48 hours, prescribed NanaBis™ (a low and high dose) and undergo frequent blood draws. These patients have all been diagnosed with cancer with managed pain. Successful completion of stage 1 is required prior to commencement of stage 2. Stage 2 is a dose escalation phase where patients have been diagnosed with advanced cancer patients and are suffering intractable pain. Their pain is unmanaged, and the dosage escalation model is set to show tolerance, as well as continuing our safety profiles. The patients' reliance on opioids will be closely monitored during this stage. An in-depth review of the Ethics agreed trial can be found at <http://www.anzctr.org.au/TrialSearch.aspx?searchTxt=12617001480370&isBasic=True>.

ISSUED FOR: MEDLAB CLINICAL LTD (ASX: MDC) – www.medlab.co

FOR FURTHER INFORMATION: DR SEAN HALL, CEO, MEDLAB CLINICAL
TEL: +61 2 8203 9520, sean_hall@medlab.co

ISSUED BY: HILL + KNOWLTON STRATEGIES, MARCHA VAN DEN HEUVEL
TEL +61 2 9286 1226 OR +61 468 960 457, marcha.vandenheuvel@hkstrategies.com

ABOUT MEDLAB – www.medlab.co

Medlab Clinical is an Australian based medical life science company, developing therapeutic pathways for diagnosed chronic diseases. It is advanced in developing therapies for pain management, depression and obesity as well as earning revenue from sale of nutritional products in Australia and the United States. In pain management Medlab is developing cannabis-based medicines. The Medlab developed nano-particle medicine delivery system, Nanocelle™, is being applied to its medicines, nutritional products and off-patent drugs like statins. Medlab has a growing patent portfolio.